In the last decade, a better understanding of the molecular pathogenesis of B-cell non-
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …

Abstract Purpose of Review Validated metrics to optimize older adult patient selection for
Chimeric Antigen Receptor T-cell therapy (CART) are lacking; however, some preliminary …

Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …

Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase
1/2 study in patients with various B-cell malignancies. In the subgroup of patients with …

Background Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein
present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate …

PURPOSE Commonly used first-line (1L) treatments for mantle cell lymphoma include high-
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …

Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on
B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and …

Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare
phenomenon with dismal prognosis, where no standard therapy exists. Since the covalent …

The data-sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is
available at www. janssen. com/clinical-trials/transparency. Requests for access to data from …